Riding Dendreons Coattails, Antigenics and Oncothyreon Shares Soar
Summary
That’s the question investors are asking today, as Dendreon’s good news from this morning is sending a ripple effect through shares of other companies that aspire to develop treatments that stimulate the immune system to fight cancer.That momentum spilled over to Antigenics (NASDAQ: AGEN), which is developing a different kind of immune boosting therapy for kidney cancer, called Oncophage.The company failed to show that treatment could slow down kidney cancer relapses, although further analysis of a subpopulation with less aggressive tumors has suggested a benefit.Antigenics stock climbed 63 percent to 77 cents at 12:13 pm Eastern today, on about eight times the average trading volume.Oncothyreon shares climbed 10 percent to $3.09 at 12:20 pm Eastern time, on about quadruple the average trading volume.
Classifications
AskAI Classifications
LabelsLinked Companies
